Co-Diagnostics Provides Earnings Guidance for the First Quarter of 2021
March 25, 2021 at 04:30 pm EDT
Share
Co-Diagnostics provided earnings guidance for the first quarter of 2021. For the first quarter of 2021, the company expects revenue for the quarter totaling between $19.0 million and $20.5 million.
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Companyâs technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the userâs mobile device.
CO-DIAGNOSTICS, INC. 
